Literature DB >> 33129443

Long-term ocrelizumab in progressive multiple sclerosis.

Deja R Rose1, Jeffrey A Cohen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33129443     DOI： 10.1016/S1474-4422(20)30399-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  1 in total

Review 1.  Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.

Authors:  Chukwunonso K Nwabufo; Omozojie P Aigbogun
Journal:  J Neurol       Date:  2022-07-13       Impact factor: 6.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.